A gene test that predicts relapse in women with ER+ early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard 5 years, according to study findings reported in a poster session at the 2018 ASCO Annual Meeting.

MONALEESA-3 Trial

Listen to Dennis J. Slamon, MD, PhD, director of Clinical/Translational Research; director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center; and executive vice chair for Research for UCLA's Department of Medicine discuss results from the MONALEESA-3.